Literature DB >> 2167709

Vaccination against SIV infection and disease.

M B Gardner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2167709     DOI： 10.1089/aid.1990.6.835

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  3 in total

1.  Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.

Authors:  B Rovinski; J R Haynes; S X Cao; O James; C Sia; S Zolla-Pazner; T J Matthews; M H Klein
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.

Authors:  K Javaherian; A J Langlois; S Schmidt; M Kaufmann; N Cates; J P Langedijk; R H Meloen; R C Desrosiers; D P Burns; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

3.  Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Authors:  E L Cooney; M J McElrath; L Corey; S L Hu; A C Collier; D Arditti; M Hoffman; R W Coombs; G E Smith; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.